Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2
Influenza vaccine GSK1562902A · 1 trial · 1 indication
Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Turkey/Turkey/01/2005 antigen. The A/Turkey/Turkey/01/2005 (A/TURK) vaccine strain was administered to groups receiving the adjuvanted Influenza vaccine GSK1562902A. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.
Any = occurrence of the symptom regardless of intensity grade. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.
| Arm | Type | Description |
|---|---|---|
| GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group | EXPERIMENTAL | Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| GSK1562902A Formulation 1 - Havrix / Havrix Jr Group | EXPERIMENTAL | Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| GSK1562902A Formulation 2 - Havrix / Havrix Jr Group | ACTIVE_COMPARATOR | Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| Havrix / Havrix Jr Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK1562902A Formulation 1 | BIOLOGICAL | Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group |
| Influenza vaccine GSK1562902A Formulation 2 | BIOLOGICAL | Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group |
| Havrix™ | BIOLOGICAL | Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group |
| Havrix™ Junior | BIOLOGICAL | Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects for whom the investigator believes that the parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol . * A male or female child 3 to 17 yea...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
Influenza vaccine GSK1562902A is an investigational vaccine developed by GSK plc for the prevention of influenza. It is a vaccine candidate that has been studied in a Phase 3 clinical trial in children. The vaccine is also referred to as Influenza vaccine GSK1562902A Formulation 1 and Formulation 2.
Influenza vaccine GSK1562902A is being developed for the prevention of influenza, a contagious respiratory illness. Its clinical evaluation has focused on use in children, specifically those aged 3 years and older. The vaccine is intended to protect against influenza infection.
Influenza vaccine GSK1562902A is developed by GSK plc, which trades on the New York Stock Exchange under the ticker GSK. GSK is the sponsor of the clinical program evaluating this influenza vaccine candidate.
Influenza vaccine GSK1562902A is in Phase 3 clinical development. The Phase 3 trial evaluating the vaccine has been completed. The vaccine is investigational and is not described as approved by the FDA.
Influenza vaccine GSK1562902A has been evaluated in one Phase 3 clinical trial, NCT01379937, titled A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children. The trial enrolled 520 participants in the Philippines and has been completed.
Yes. Influenza vaccine GSK1562902A is also known as Influenza vaccine GSK1562902A Formulation 1 and Influenza vaccine GSK1562902A Formulation 2. These names refer to the same GSK influenza vaccine candidate studied in the Phase 3 trial NCT01379937.